Article

Katena, IOP Ophthalmics combine

Katena has announced its acquisition of IOP Ophthalmics of Costa Mesa, CA.

 

Denville, NJ-Katena has announced its acquisition of IOP Ophthalmics of Costa Mesa, CA.

Terms of the transaction have not been disclosed.

IOP Ophthalmics-a company that develops, commercializes, and distributes specialty ophthalmic surgical devices and biologics-holds market leadership positions with amniotic membrane technologies for ocular surface, glaucoma, and oculoplastic indications; devices for glaucoma and oculoplastic indications; and bioimplants for general ophthalmic surgeries.

“This combination of two great companies not only creates greater critical mass in the ophthalmology marketplace, but it enhances our ability to provide more clinical solutions and be of greater value to our customers,” said Bill Friedberg, president and chief executive officer of Katena.

Jason Malecka, president and founder of IOP-along with Erich Ziegler, vice president and chief financial officer of IOP-will continue their relationship with the combined company, and will continue in their roles focusing on global product growth.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.